“…Cys-C has been extensively studied in the context of HF. It is largely accepted nowadays that Cys-C is a fine surrogate marker of glomerular filtration rate (GFR), 2 and not involved in heart remodelling 3 nor in the pathogenesis of cardiovascular diseases. 4 Similarly, the initial hope with Gal-3, has been dismantled by studies showing that it is, again, merely a marker of GFR that does not add prognostic information after correcting for renal function, 5 nor is it involved in the pathogenesis of fibrotic changes at a myocardial level in HF from hypertensive origin.…”